BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, March 12, 2026
Home » Newsletters » BioWorld Asia

BioWorld Asia

Oct. 2, 2002

View Archived Issues

Germany Closing Neuer Markt Amid Mounting Losses, Scandals

MUNICH, Germany - Deutsche Boerse AG, the company that operates Germany's most important stock markets, is closing the Neuer Markt as part of a larger restructuring in the company's exchanges. The market was launched in March 1997 to expand the opportunities for high-growth, high-technology companies to raise capital in public markets. (BioWorld International) Read More

Investors Hammer Genmab Stock Following Failure Of Lead Drug

Read More

Cellular Immune Response Clues Could Aid Vaccine Development

Read More

Cytos Going Public By Way Of Merger With Swiss Company

Read More

Pharming Raises EUR8.2M In Equity, Debt, Prepares To Exit Moratorium

Read More

Other News To Note

Read More

Improving Processes Key For Helping Companies Raise Profits

Read More

NicOx Grants AstraZeneca Exclusive License For Japan

Read More

OGS Restructures To Focus On Storage Disorders, Oncology

Read More

Red Cross Speaks Out About Potential Biotechnology Abuse

Read More

Europe Steps Up Campaign To Break Myriad's Hold On BRCA1

Read More

Vernalis Hoping To Break Even In 2004 With Frovatriptan Success

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 11, 2026.
  • Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

    Cas and effect: Merck’s phase III ripples HIF-2α space

    BioWorld
    Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
  • Tanycytes in green capturing tau protein in red.

    Brain’s hidden tau-clearing pathway uncovered

    BioWorld Science
    Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 10, 2026
  • MSD synthesizes α-synuclein PET agents

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing